PMID- 37789213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240422
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 14
IP  - 12
DP  - 2023 Dec
TI  - LIVE INDIA: Effectiveness of Gla-100 in a Post hoc Pooled Analysis of FINE ASIA 
      and GOAL Registries.
PG  - 2075-2088
LID - 10.1007/s13300-023-01469-3 [doi]
AB  - INTRODUCTION: Real-world evidence on insulin glargine 100 U/ml (Gla-100) 
      initiation in Indian type 2 diabetes mellitus (T2DM) individuals is limited. The 
      present study aimed to evaluate the effectiveness of Gla-100 in insulin-naive 
      T2DM participants from India. METHODS: This post hoc analysis includes real-world 
      data of insulin-naive Indian participants with T2DM who started Gla-100 treatment 
      in two Asian registries: FINE ASIA and GOAL. Changes in glycated hemoglobin 
      (HbA1c), fasting plasma glucose (FPG), body weight, insulin dose, and incidence 
      of hypoglycemia from baseline to 6 months were assessed. RESULTS: A total of 955 
      participants with T2DM were identified and analyzed. The mean [standard deviation 
      (SD)] age and duration of diabetes were 54.7 (9.8) years and 9.8 (6.3) years, 
      respectively. Mean HbA1c and FPG were significantly reduced after 6 months of 
      Gla-100 treatment [- 2.07 (1.4) %; - 94.4 (65.2) mg/dl, respectively]. HbA1c 
      targets of < 7.0% and < 7.5% were achieved by 292 (30.6%) and 589 (61.7%) study 
      participants, respectively. The overall incidence of hypoglycemia was low 
      (n = 52; 5.4%); only two participants (0.2%) reported severe hypoglycemia. 
      Insulin was titrated with a mean (SD) increment of 2.5 (5.6) U/day after 
      6 months, leading to a mean Gla-100 dose of 18.2 (8.9) U/day. Mean body weight 
      remained unchanged from baseline to 6 months (- 0.1 kg). CONCLUSION: In routine 
      clinical practice, Gla-100 significantly improved glycemic parameters after 
      6 months of treatment with a low risk of hypoglycemia and no weight change in 
      participants with T2DM.
CI  - (c) 2023. The Author(s).
FAU - Deshmukh, Vaishali
AU  - Deshmukh V
AD  - Deshmukh Clinic and Research Centre, Second Floor, Pinnacle Prestige, Landmark: 
      Next to Durvankur Hotel, Near Cosmos Bank, Tilak Road, Pantancha Gate, Sadashiv 
      Peth, Pune, Maharashtra, 411030, India. dcrcpune@gmail.com.
FAU - Chaudhury, Tirthankar
AU  - Chaudhury T
AD  - Apollo Gleneagles Hospitals, Kolkata, India.
FAU - Chadha, Manoj
AU  - Chadha M
AD  - P.D. Hinduja Hospital and Research Centre, Mumbai, India.
FAU - Chawla, Manoj
AU  - Chawla M
AD  - Lina Diabetes Care Centre, Mumbai, India.
FAU - Mukherjee, Sagarika
AU  - Mukherjee S
AD  - Dr. Sagarika Mukherjee's Clinic, Kolkata, India.
FAU - Pitale, Shailesh
AU  - Pitale S
AD  - DEW Medicare and Trinity Hospital, Nagpur, India.
FAU - Basu, Debasis
AU  - Basu D
AD  - METTA Clinic, Kolkata, India.
FAU - Gadekar, Arvind
AU  - Gadekar A
AD  - Sanofi, Mumbai, India.
FAU - Menon, Shalini
AU  - Menon S
AD  - Sanofi, Mumbai, India.
FAU - Trivedi, Chirag
AU  - Trivedi C
AD  - Sanofi, Mumbai, India.
FAU - Salvi, Vaibhav
AU  - Salvi V
AD  - Sanofi, Mumbai, India.
FAU - Ramakrishnan, Santosh
AU  - Ramakrishnan S
AD  - Magna Clinics for Obesity Diabetes and Endocrinology, Hyderabad, India.
FAU - Goyal, Ghanshyam
AU  - Goyal G
AD  - S K Diabetes Research and Education Centre, S V S Marwari Hospital Campus, 
      Kolkata, India.
LA  - eng
PT  - Journal Article
DEP - 20231004
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC10597908
OTO - NOTNLM
OT  - Basal insulin
OT  - Glargine
OT  - Pooled analysis
OT  - Post hoc analysis
OT  - Type 2 diabetes
COIS- Manoj Chadha has received speaker fees from Eli Lilly and Company, Novo Nordisk 
      and Sanofi. Manoj Chawla is on the advisory board for/has a speaker contract 
      with/has a consultancy agreement with Sanofi India, Novo Nordisk India Pvt. Ltd., 
      Eli Lilly India, Boehringer Ingelheim, MSD, AstraZeneca Pharma India Ltd., 
      Novartis, Eris Lifesciences, and USV. Vaishali Deshmukh, Tirthankar Chaudhury, 
      Sagarika Mukherjee, Shailesh Pitale, Debasis Basu, Santosh Ramakrishnan, 
      Ghanshyam Goyal have nothing to disclose. Arvind Gadekar, Shalini Menon, Chirag 
      Trivedi, and Vaibhav Salvi are employees of Sanofi and may hold stock options. 
      The authors individually and collectively are responsible for all content and 
      editorial decisions and did not receive any payment from Sanofi directly or 
      indirectly (through a third party) related to the development or presentation of 
      this study.
EDAT- 2023/10/04 00:42
MHDA- 2023/10/04 00:43
PMCR- 2023/10/04
CRDT- 2023/10/03 23:39
PHST- 2023/04/28 00:00 [received]
PHST- 2023/08/31 00:00 [accepted]
PHST- 2023/10/04 00:43 [medline]
PHST- 2023/10/04 00:42 [pubmed]
PHST- 2023/10/03 23:39 [entrez]
PHST- 2023/10/04 00:00 [pmc-release]
AID - 10.1007/s13300-023-01469-3 [pii]
AID - 1469 [pii]
AID - 10.1007/s13300-023-01469-3 [doi]
PST - ppublish
SO  - Diabetes Ther. 2023 Dec;14(12):2075-2088. doi: 10.1007/s13300-023-01469-3. Epub 
      2023 Oct 4.